Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

Annals of Internal Medicine

Volumn 135, Issue 1, 2001, Pages 17-26

  Murphy, E L ^a   Collier, A C ^a   Kalish, L A ^a   Assmann, S F ^a   Para, M F ^a   Flanigan, T P ^a   Kumar, P N ^a   Mintz, L ^a   Wallach, F R ^a   Nemo, G J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SEROCONVERSION;

EID: 0035800026     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-1-200107030-00005     Document Type: Article

References (35)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Effectiveness of potent anti-retroviral therapy on time to AIDS and death in men with known HIV infection duration
4. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997
5. HIV disease progression in Australia in the time of combination antiretroviral therapies
6. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
7. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy
8. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland
9. Changing patterns of mortality across Europe in patients infected with HIV-1
10. Increasing survival time after AIDS in Italy: The role of new combination antiretroviral therapies
11. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors
12. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
13. 3
14. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project
15. The Viral Activation Transfusion Study (VATS): Rationale, objectives, and design overview
16. Double-blinded randomized study of leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: Results of the Viral Activation Transfusion Study
17. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
18. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
19. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
20. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
21. An empirical Bayes approach to the estimation of the incidence curve of HIV infection
22. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening
23. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
24. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS
25. Temporal trends and factors associated with survival after Pneumocystis carinii pneumonia in California, 1983-1992
26. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
27. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors
28. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy
29. Decreased incidence of CMV disease unrelated to use of HAART
30. Impact of combination therapy for HIV infection on inpatient census
31. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
32. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients